Promoting healthy skepticism in the news: helping journalists get it right.

Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Med (2012) 3.33

Media coverage of medical journals: do the best articles make the news? PLoS One (2014) 0.96

Re: promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2011) 0.75

Re: Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2010) 0.75

Re: Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2010) 0.75

Can facts trump unconditional trust? Evidence-based information halves the influence of physicians' non-evidence-based cancer screening recommendations. PLoS One (2017) 0.75

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75

Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med (1992) 7.65

Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med (1992) 6.68

Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst (2009) 6.21

The framing effect of relative and absolute risk. J Gen Intern Med (1993) 4.87

Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ (1995) 4.75

Press releases: translating research into news. JAMA (2002) 3.41

Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making (1995) 3.21

Press releases by academic medical centers: not so academic? Ann Intern Med (2009) 1.91

Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ (2006) 1.70

Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13

Enthusiasm for cancer screening in the United States. JAMA (2004) 8.22

When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ (2013) 8.12

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45

The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43

Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain (2004) 6.32

A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62

Too Little? Too Much? Primary care physicians' views on US health care: a brief report. Arch Intern Med (2011) 4.53

Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med (2011) 4.53

Lost in transmission--FDA drug information that never reaches clinicians. N Engl J Med (2009) 4.12

New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85

Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79

Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA (2003) 3.57

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51

Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ (2010) 3.46

Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med (2009) 3.44

Press releases: translating research into news. JAMA (2002) 3.41

Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med (2011) 3.38

Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04

Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med (2012) 3.01

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01

Risk charts: putting cancer in context. J Natl Cancer Inst (2002) 2.96

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82

Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79

Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ (2005) 2.73

The value of benefit data in direct-to-consumer drug ads. Health Aff (Millwood) (2004) 2.68

Tobacco money: up in smoke? Lancet (2002) 2.68

Screening for cervical cancer: will women accept less? Am J Med (2005) 2.68

Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med (2011) 2.63

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38

Reducing the risk that patients get it wrong. Gastroenterology (2005) 2.38

Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26

Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26

The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst (2008) 2.25

Communicating data about the benefits and harms of treatment: a randomized trial. Ann Intern Med (2011) 2.21

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst (2005) 2.15

Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10

Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak (2013) 1.99

Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91

Giving legs to restless legs: a case study of how the media helps make people sick. PLoS Med (2006) 1.91

Press releases by academic medical centers: not so academic? Ann Intern Med (2009) 1.91

Advertising by academic medical centers. Arch Intern Med (2005) 1.84

What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest (2013) 1.79

The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76

The media matter: a call for straightforward medical reporting. Ann Intern Med (2004) 1.74

Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ (2006) 1.70

Media coverage of scientific meetings: too much, too soon? JAMA (2002) 1.69

Distribution of C-reactive protein values in the United States. N Engl J Med (2005) 1.69

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64

Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60

Can patients interpret health information? An assessment of the medical data interpretation test. Med Decis Making (2005) 1.59

News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer. JAMA (2002) 1.58

How do elderly patients decide where to go for major surgery? Telephone interview survey. BMJ (2005) 1.58

The benefits and harms of mammography screening: understanding the trade-offs. JAMA (2010) 1.57

National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56

The exaggerated relations between diet, body weight and mortality: the case for a categorical data approach. CMAJ (2005) 1.54

Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52

Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52

The word "cancer": how language can corrupt thought. BMJ (2013) 1.51

The drug facts box: providing consumers with simple tabular data on drug benefit and harm. Med Decis Making (2007) 1.45

A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45

A population approach to precision medicine. Am J Prev Med (2012) 1.44

Implications of expanding disease definitions: the case of osteoporosis. Health Aff (Millwood) (2007) 1.42

Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study. BMJ (2012) 1.41

Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40

American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29

Celebrity endorsements of cancer screening. J Natl Cancer Inst (2005) 1.28

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28

Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27

Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol (2002) 1.27

Patients and medical statistics. Interest, confidence, and ability. J Gen Intern Med (2005) 1.27

Media reporting on research presented at scientific meetings: more caution needed. Med J Aust (2006) 1.26

Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. BMJ (2006) 1.22